BIOA — BioAge Labs, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1709941 ·
Last close
$9.38
Market Cap
$430.51M
52W High
$25.95
52W Low
$8.65
ADV30
1,100,322
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 2,451,000 | — | -29,333,000 | -26,097,000 | 396,929,000 | 73,964,000 | 22,016,000 |
| Mar 2026 | 2,772,000 | — | -25,375,000 | -22,253,000 | 397,654,000 | 241,777,000 | 18,533,000 |
| Dec 2025 | 3,078,000 | — | -28,423,000 | -25,943,000 | 294,889,000 | 188,888,000 | 22,838,000 |
| Sep 2025 | 2,054,000 | — | -23,140,000 | -20,171,000 | 305,090,000 | 215,573,000 | 27,626,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,601,000
Investing CF
$-212,854,000
Financing CF
$154,150,000
CapEx
$-488,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.26
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-381,766,000
Inventory
—
Receivables
$625,000
ST Investments
$244,781,000
EBIT TTM
$-94,183,000
Pretax Income TTM
$-94,464,000
Interest Exp TTM
$281,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,355,000
EBITDA
$-106,020,000
Free Cash Flow
$-58,067,000
Enterprise Value
$119,192,696
Total Cash
$318,744,992
Total Debt
$2,835,000
Shares Out
45,896,909
Trailing EPS
$-2.39
Book Value
$8.19
ROE
-28.2%
ROA
-18.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 8,995,000 | -92,780,000 | -80,605,000 | 294,889,000 | 22,838,000 | — | -81,627,000 |
| Dec 2024 | 0 | -78,194,000 | -71,109,000 | 358,234,000 | 35,107,000 | — | -51,522,000 |
| Dec 2023 | 0 | -48,400,000 | -63,854,000 | 25,924,000 | 199,320,000 | — | -37,362,000 |
| Dec 2022 | 0 | -39,969,000 | -39,722,000 | 28,429,000 | 140,988,000 | — | -36,181,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.36
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $9.38 · call volume: 886 · put volume: 32
Expected Move to 2026-09-18:
±$1.41
(15.03%) —
implied range
$7.97 –
$10.79
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BNTC | Benitec Biopharma Inc. | $436.64M | $12.71 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $440.38M | $0.42 | — |
| LRMR | Larimar Therapeutics, Inc. | $420.73M | $4.05 | — |
| PRLD | Prelude Therapeutics Inc | $420.01M | $6.47 | — |
| AVIR | Atea Pharmaceuticals, Inc. | $441.93M | $5.51 | — |
News headlines (Yahoo Finance, 1h cache)
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
2026-08-06 00:35 · Yahoo
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-05 20:50 · Yahoo
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
2026-07-31 21:56 · Yahoo
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?
2026-06-30 13:09 · Yahoo
BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor
2026-06-25 00:22 · Yahoo
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
2026-06-16 12:00 · Yahoo
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
2026-06-06 12:04 · Yahoo
BioAge Labs to Present at Upcoming Investor Conferences
2026-05-22 13:00 · Yahoo
This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday
2026-05-13 17:43 · Yahoo
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33
2026-05-13 12:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.